Show simple item record

dc.contributor.authorTombal, BF
dc.contributor.authorLoriot, Y
dc.contributor.authorSaad, F
dc.contributor.authorMcDermott, RS
dc.contributor.authorElliott, Tony
dc.contributor.authorRodriguez-Vida, A
dc.contributor.authorNole, F
dc.contributor.authorFournier, B
dc.contributor.authorCollette, L
dc.contributor.authorGillessen, Silke
dc.date.accessioned2019-11-19T16:01:08Z
dc.date.available2019-11-19T16:01:08Z
dc.date.issued2019en
dc.identifier.citationTombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, et al. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysis. J Clin Oncol. 2019;37(15_suppl):5007-.en
dc.identifier.doi10.1200/JCO.2019.37.15_suppl.5007en
dc.identifier.urihttp://hdl.handle.net/10541/622470
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2019.37.15_suppl.5007en
dc.titleDecreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: an interim safety analysisen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentUniversit� Catholique de Louvain, Brussels, Belgiumen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record